Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "business-development"

154 News Found

Navia Life Care raises US $ 1 million in Series A funding
Startup | August 20, 2021

Navia Life Care raises US $ 1 million in Series A funding

The company plans to invest in technology, business development, product innovation, and development across India


HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY
Healthcare | August 13, 2021

HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY

Substantial reduction in losses


Amring Pharmaceuticals launch Isoproterenol Hydrochloride Injection USP
News | August 10, 2021

Amring Pharmaceuticals launch Isoproterenol Hydrochloride Injection USP

The drug is indicated for mild and transient episodes of heart block


We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.


Stelis Biopharma appoints Mark W. Womack as CEO
People | August 07, 2021

Stelis Biopharma appoints Mark W. Womack as CEO

He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations


Bafna Pharma posts Q1FY 21-22 net at Rs. 2.08 Cr
News | August 07, 2021

Bafna Pharma posts Q1FY 21-22 net at Rs. 2.08 Cr

This robust growth has come despite the raging pandemic for most part of the quarter


Mark W. Womack is the new CEO of Stelis Biopharma
Biotech | August 06, 2021

Mark W. Womack is the new CEO of Stelis Biopharma

He will be stationed at the company HQ in Bengaluru, India


'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.
Interviews | June 10, 2021

'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.

In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:


Bayer acquires Noria and PSMA Therapeutics
News | June 07, 2021

Bayer acquires Noria and PSMA Therapeutics

Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)


Bharat Biotech ramping up manufacturing capacity to 70 Cr doses: Dr. Raches Ella
People | May 23, 2021

Bharat Biotech ramping up manufacturing capacity to 70 Cr doses: Dr. Raches Ella

We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity